Bevacizumab biosimilar (Hualan Biological Engineering)

贝伐珠单抗生物类似药（华兰基因工程）

Report date: 2024/11/22 17:18:22

Base Information

Drug NameBevacizumab biosimilar (Hualan Biological Engineering)
Drug Alias Name贝伐单抗生物仿制药（华兰基因工程）贝伐珠单抗生物仿制药（华兰基因工程）贝伐人源化单抗生物仿制药（华兰基因工程）贝伐赛珠单抗生物仿制药（华兰基因工程）WBP-264
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[8] 
Global Approved IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[8] 
Approved Indications in ChinaUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[8] 
Original Approved Country/TerritoryMainland China
Original Approved Date2024/11/15
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesHualan Ankang Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHualan Ankang Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XC07
Related LinksN/A